

Genital Herpes - Pipeline Insight, 2021

<https://marketpublishers.com/r/G0F0DDA0D266EN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: G0F0DDA0D266EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Genital Herpes – Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Genital Herpes Understanding

Genital Herpes: Overview

Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors ¹. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. The first signs of genital herpes usually show up two to 12 days after having sexual contact with someone who has herpes. Symptoms can last from two to four weeks. There are other early symptoms of genital herpes: Feeling of pressure in the abdomen, Flu-like symptoms, including fever, Itching or burning feeling in the genital or anal area, Pain in the legs, buttocks, or genital area, Swollen glands,

and Unusual vaginal discharge. The laboratory diagnosis of acute genital HSV infection or asymptomatic virus shedding is made via direct viral detection. The method of choice is demonstration of viral genomes in skin or mucous membrane swabs using the polymerase chain reaction (PCR). Standard first-line drugs include acyclovir, valacyclovir and famciclovir. The specific antiviral action of these acyclic nucleoside analogues is based on their phosphorylation to monophosphate form by thymidine kinase (TK), the key enzyme of HSV-1 and HSV-2, with subsequent phosphorylation via di- to triphosphate form by cellular enzymes.

'Genital Herpes - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital Herpes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve Genital Herpes.

Genital Herpes Emerging Drugs Chapters

This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Genital Herpes Emerging Drugs

Pritelivir: AiCuris

Pritelivir is a new small molecule, a helicase-primase inhibitor with a novel mode of action. The drug is in phase III stage of development for the treatment of Genital Herpes. Pritelivir has a mode of action that is distinct from other antiviral agents currently in use for treating HSV infections (i.e., the nucleoside analogs acyclovir and its prodrug valacyclovir as well as famciclovir, the prodrug of penciclovir). While nucleoside analogs terminate ongoing DNA chain elongation through inhibition of viral DNA polymerase, pritelivir prevents de novo synthesis of viral DNA through inhibition of the helicase-primase complex. In addition, it does not require activation within an HSV infected cell by viral thymidine kinase and is therefore also protective to uninfected cells. In June 2020, AiCuris was granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the treatment of HSV infections in immunocompromised patients.

UB-621: United Biopharma

UB-621 is a human IgG1 monoclonal antibody that targets conserved gD protein of Herpes simplex virus (HSV) type I and type II. The drug is in phase II stage of development for the treatment of Genital Herpes. It has been shown in vitro to block HSV infections of both wild type and acyclovir-resistant viral strains with over hundreds-fold higher potency.

HDIT 101: Heidelberg ImmunoTherapeutics

HDIT 101, a humanized monoclonal antibody is being developed by Heidelberg ImmunoTherapeutics GmbH for the treatment of human herpes simplex virus (HSV) infections. The drug is currently in phase II stage of development for the treatment of Genital Herpes.

Further product details are provided in the report.....

Genital Herpes: Therapeutic Assessment

This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Genital Herpes

There are approx. 25+ key companies which are developing the therapies for Genital Herpes. The companies which have their Genital Herpes drug candidates in the most advanced stage, i.e. Phase III include, AiCuris.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Genital Herpes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.

Genital Herpes Report Insights

Genital Herpes Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Genital Herpes Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Genital Herpes drugs?

How many Genital Herpes drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Herpes?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Genital Herpes and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- Genital Herpes: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Pritelivir: AiCuris
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- UB-621: United Biopharma
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early stage products (Phase I/II)
 - Comparative Analysis
- HSV 2 Vaccines: Sanofi
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Genital Herpes Key Companies

Genital Herpes Key Products

Genital Herpes- Unmet Needs

Genital Herpes- Market Drivers and Barriers

Genital Herpes- Future Perspectives and Conclusion

Genital Herpes Analyst Views

Genital Herpes Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Genital Herpes

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Genital Herpes
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Genital Herpes - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/G0F0DDA0D266EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0F0DDA0D266EN.html>